William Welsh, DO
Geriatric Medicine · Whittier, CANPI 1568401255
Payments from drug & device makers
Across 583 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- AbbVie$1K
- Amgen$1K
- AstraZeneca$1K
- Lilly USA, LLC$950
- GSK$780
- plus $6K from 48 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Consulting fees$1,2009%
- Travel & lodging$2282%
- Food & beverage$11,61389%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,508
- Otezla$124
How this compares
$13,047 in reported general payments places this provider in the 95th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 415 | $456,624 |
| EliquisApixaban | 438 | $343,225 |
| JardianceEmpagliflozin | 171 | $164,880 |
| FarxigaDapagliflozin Propanediol | 111 | $117,084 |
| TrulicityDulaglutide | 83 | $94,395 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $93,428 |
| ProliaDenosumab | 42 | $69,930 |
| TradjentaLinagliptin | 95 | $63,133 |
| MounjaroTirzepatide | 44 | $54,949 |
| JanuviaSitagliptin Phosphate | 63 | $50,149 |
| XareltoRivaroxaban | 83 | $49,967 |
| Repatha SureclickEvolocumab | 53 | $35,556 |
| Repatha SyringeEvolocumab | 58 | $34,457 |
| GemtesaVibegron | 32 | $32,785 |
| ProcritEpoetin Alfa | 34 | $30,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $690 | $456,624415 claims |
| PfizerEliquis | $459 | $343,225438 claims |
| Boehringer IngelheimJardiance, Tradjenta | $315 | $228,012266 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $950 | $149,344127 claims |
| AstraZenecaFarxiga, Brilinta | $1,020 | $124,101140 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $780 | $111,621166 claims |
| AmgenProlia, Evenity (2 Syringes) | $1,138 | $93,60753 claims |
| Johnson & JohnsonXarelto, Procrit | $195 | $80,348117 claims |
| MerckJanuvia | $214 | $50,14963 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $194 | $32,78532 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $293 | $22,51929 claims |
| AbbVieLinzess | $1,266 | $17,44220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in Whittier
- Michael MaguireWhittier$8K
- Paul AisenSan Diego$15.7M
- Kanagaratnam SivalingamLancaster$2.4M
- Wayne ChenLos Angeles$2M
- Robert FeldmanLaguna Hills$1.9M
- Isabel PereiraFountain Valley$1.2M
- Timothy ParenteauOakland$221K
- Oscar ChienSan Gabriel$208K
- Anna ChangSan Francisco$170K
- Anders NybergSan Diego$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.